BDKRB1 and glioma: One possible concern about the use of exogenous selective B1R (or B2R) kinins as BTB disruptors in adjuvant glioma therapy is that they can potentially act as mitogens with pro-migratory activity (at least in vitro) and may thereby accelerate disease progression [71], [72], [73].